Endo International Plc (NASDAQ:ENDP)

About the company

Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The firm operates through the following segments: U.S. Branded-Specialty & Established Pharmaceuticals, U.S. Branded-Sterile Injectables, U.S. Generic Pharmaceuticals and International Pharmaceuticals. The U.S. Branded-Specialty & Established Pharmaceuticals segment offers prescription products to treat and manage conditions in urology, urologic oncology, endocrinology, pain and orthopedics. The U.S. Branded-Sterile Injectables segment consists primarily of branded sterile injectable products such as VASOSTRICT, ADRENALIN and APLISOL, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection, among others. The U.S. Generic Pharmaceuticals segment consists of a differentiated product portfolio including solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmics and sprays and includes products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health and cardiovascular disease markets, among others. The International Pharmaceuticals segment includes a variety of pharmaceutical products for the Canadian, Latin American, South African, and world markets. The company was founded in 1997 and is headquartered Dublin, Ireland.

Sector

Health Technology

Industry

Pharmaceuticals: Other

Employees

3172

CEO

Blaise Coleman

Exchange

NASDAQ

Website

http://www.endo.com

$3B

Total Revenue

3K

Employees

$784.32M

Market Capitalization

-2.80

Price/Earning ratio

Stock price

Gross Margin (in %)

Total gross margin

$1447M

Operating Margin (in %)

Total operating margin

$672M

Net Margin (in %)

Total net margin

$-274M

Dividend Yield (in %)

Dividend per share

$0

Industry peers

Name Ticker Market capitalization (in USD Million) Revenues (in USD Million) Price/Book Price/Earning Net margin (in %)
Horizon Therapeutics Plc HZNP 12180.00 1376.00 5.19 19.21 43.06
Catalent, Inc. CTLT 10896.37 2872.00 5.47 104.47 3.63
Perrigo Co. Plc PRGO 7558.29 4837.00 1.30 51.56 3.02
Jazz Pharmaceuticals Plc JAZZ 6076.20 2188.00 2.10 22.21 12.81
Bausch Health Cos., Inc. BHC 6068.07 8597.00 8.47 -3.21 -21.96
United Therapeutics Corp. UTHR 5049.92 1443.00 1.75 9.75 36.59
MyoKardia, Inc. MYOK 4249.02 34.00 12.35 -13.70 -201.73
Axsome Therapeutics, Inc. AXSM 2906.40 None 19.72 -32.31 None
Pacira Biosciences, Inc. PCRX 2427.60 435.00 6.51 -5780.00 -0.02
SAGE Therapeutics, Inc. SAGE 2295.80 9.00 2.70 -3.55 -413.06
ArQule, Inc. ARQL 2240.00 5.00 15.75 -55.56 -808.06
Corcept Therapeutics, Inc. CORT 2013.00 335.00 4.62 18.97 31.64
Prestige Consumer Healthcare, Inc. PBH 1863.54 963.00 1.57 13.14 14.77
Revolution Medicines, Inc. RVMD 1798.91 48.00 4.67 -25.41 -146.29
Madrigal Pharmaceuticals, Inc. MDGL 1558.65 0.00 4.16 -15.26 -624.74
Ironwood Pharmaceuticals, Inc. IRWD 1548.02 440.00 -21.91 18.26 19.14
Innoviva, Inc. INVA 1534.54 285.00 3.63 7.94 66.41
Intercept Pharmaceuticals, Inc. ICPT 1446.72 272.00 -43.06 -4.22 -127.53
Portola Pharmaceuticals, Inc. PTLA 1329.78 121.00 19.53 -4.77 -232.73
Supernus Pharmaceuticals, Inc. SUPN 1309.50 402.00 2.08 11.23 28.90
Theravance Biopharma, Inc. TBPH 1232.34 88.00 -8.65 -4.99 -280.80
Zogenix, Inc. ZGNX 1225.80 5.00 3.35 -2.88 -241.62
Revance Therapeutics, Inc. RVNC 1161.84 0.00 4.59 -6.23 41.82
Amphastar Pharmaceuticals, Inc. AMPH 996.66 327.00 2.49 19.56 15.90
Endo International Plc ENDP 784.32 3014.00 -1.07 -2.80 -9.09
BellRing Brands, Inc. BRBR 745.68 954.00 -0.40 5.66 13.98
Eagle Pharmaceuticals, Inc. EGRX 678.30 192.00 3.65 269.17 1.29
Assembly Biosciences, Inc. ASMB 667.58 16.00 2.99 -6.71 -601.75
Aerie Pharmaceuticals, Inc. AERI 613.18 79.00 4.86 -3.03 -252.92
Collegium Pharmaceutical, Inc. COLL 582.76 299.00 4.17 -45.11 -4.21
Intersect ENT, Inc. XENT 577.76 102.00 5.45 -11.57 -48.61
Catalyst Pharmaceuticals, Inc. CPRX 528.58 119.00 5.15 12.05 36.09
Anika Therapeutics, Inc. ANIK 486.78 125.00 1.68 17.56 22.73
BioDelivery Sciences International, Inc. BDSI 388.24 130.00 5.55 -52.75 -5.01
Albireo Pharma, Inc. ALBO 326.82 11.00 3.32 -4.28 -730.55
ANI Pharmaceuticals, Inc. ANIP 326.76 203.00 1.67 -209.46 -0.67
MEI Pharma, Inc. MEIP 275.56 5.00 4.74 -7.06 -539.48
Mallinckrodt Plc MNK 199.08 3037.00 0.11 -0.17 -39.56
Agile Therapeutics, Inc. AGRX 147.85 None 2.41 -7.16 None
Marinus Pharmaceuticals, Inc. MRNS 146.79 0.00 5.68 -2.18 None
Cerecor, Inc. CERC 118.22 7.00 7.56 -5.24 -429.22
Ampio Pharmaceuticals, Inc. AMPE 98.67 1.00 69.00 -5.31 None
Evoke Pharma, Inc. EVOK 85.92 None 29.83 -12.79 None
Zynerba Pharmaceuticals, Inc. ZYNE 85.79 0.00 1.41 -2.39 -699.94
AcelRx Pharmaceuticals, Inc. ACRX 84.80 2.00 -1.56 -1.51 -644.25
Aclaris Therapeutics, Inc. ACRS 73.80 4.00 1.29 -0.54 None
CTI BioPharma Corp. CTIC 71.98 3.00 3.21 -1.74 -111.83
Adamas Pharmaceuticals, Inc. ADMS 70.84 57.00 -4.52 -0.76 -160.44
Cassava Sciences, Inc. SAVA 63.46 41.00 3.34 -13.92 76.71
Oramed Pharmaceuticals, Inc. ORMP 59.94 3.00 4.83 -4.69 -464.15
SCYNEXIS, Inc. SCYX 48.28 0.00 10.14 -1.25 -30.84
Cumberland Pharmaceuticals, Inc. CPIX 47.70 47.00 0.97 -10.60 -9.59
Natural Alternatives International, Inc. NAII 47.67 114.00 0.65 -12.61 -3.19
IsoRay, Inc. ISR 44.22 9.00 8.25 -13.20 -36.08
Lipocine, Inc. LPCN 40.20 0.00 9.57 -2.68 None
Acasti Pharma, Inc. ACST 35.84 827.00 2.33 -0.58 -7.45
Neos Therapeutics, Inc. NEOS 34.50 65.00 -2.65 -1.97 -26.74
PLx Pharma, Inc. PLXP 25.65 0.00 -2.46 -2.71 119.04
CytRx Corp. CYTR 22.11 0.00 1.60 -3.19 408.46
EyeGate Pharmaceuticals, Inc. EYEG 19.92 3.00 2.48 -1.68 -264.21
Regulus Therapeutics, Inc. RGLS 17.22 0.00 1.52 -0.80 -272.13
Tetraphase Pharmaceuticals, Inc. TTPH 12.15 8.00 0.64 -0.14 -798.18
Intec Pharma Ltd. NTEC 10.18 None 1.31 -0.24 None
Hepion Pharmaceuticals, Inc. HEPA 7.38 None 2.31 -0.62 None
Sonoma Pharmaceuticals, Inc. SNOA 6.44 19.00 1.02 -2.06 -25.58
KemPharm, Inc. KMPH 6.02 15.00 -0.17 -0.35 -120.48
VIVUS, Inc. VVUS 5.83 73.00 -0.13 -0.20 -39.28
Tonix Pharmaceuticals Holding Corp. TNXP 4.62 None 1.16 -0.10 None
Ritter Pharmaceuticals, Inc. RTTR 0.45 None 0.17 -0.03 None

Latest insider transactions

Date Role Name Transaction Quantity Quantity Owned After

Endo (ENDP) Obtains FDA Approval for Cellulite Treatment

3d ago, source: YAHOO!

Endo (ENDP) gains FDA approval for Qwo (collagenase clostridium histolyticum-aaes) for the treatment of cellulite.

Endo International Plc (NASDAQ: ENDP) Investor Alert: Lawsuit Alleges False and Misleading Statements

9d ago, source: Digital Journal

A lawsuit was filed on behalf of investors in Endo International plc (NASDAQ: ENDP) shares over alleged securities laws violations. This press release was orginally distributed by SBWire San Diego, CA ...

Endo Shareholder Alert: Faruqi & Faruqi, LLP Encourages Investors Who ...

3d ago, source: Middle East North Africa Financial Network

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Endo International plc To Contact The Firm New York, New York--(Newsfile Corp. - July 7, 2020) - Faruqi & ...

ENDP INVESTOR LAWSUIT ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit has been Filed Against Endo International plc

10d ago, source: YAHOO!

Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action has been filed ...

Shareholder Alert: Robbins LLP Announces Endo International Plc (ENDP) Sued for Misleading Shareholders

14d ago, source: Business Wire

Shareholder rights law firm Robbins LLP announces that a purchaser of Endo International Plc (NASDAQ: ENDP) filed a class ...

FDA Approves Endo's Qwo To Treat Cellulite

4d ago, source: Business Insider

(RTTNews) - Endo International plc (ENDP) said that the U.S. Food and Drug Administration has approved Qwo for the treatment of moderate to ...

U.S. FDA Approves Qwo™ (collagenase clostridium histolyticum-aaes), the First Injectable Treatment for Cellulite

4d ago, source: MarketWatch

DUBLIN, July 6, 2020 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that it received U.S. Food and Drug Administration (FDA) approval of Qwo™ (collagenase clostridium ...



Portfolio items

Follow companies to create your optimal portfolio.
or
Refresh this page to see your newly added stocks.